Synonyms: VERU-111 | VERU111
Compound class:
Synthetic organic
Comment: Sabizabulin (VERU-111) is an orally bioavailable βIII/βIV-tubulin inhibitor that was developed for anti-tumour potential [1-2]. It interacts with the tubulin colchicine binding site. VERU-111 induces mitotic arrest and apoptosis in cancer cells in vitro, and inhibits xenograft tumour growth. It is suggested that like colchicine, VERU-111 may have anti-viral and anti-inflammatory actions in addition to its antiproliferative activity.
COVID-19: Sabizabulin has been repositioned as a potential therapeutic for COVID-19; in particular for patients who are hospitalised with moderate to severe COVID-19 and who are at high risk for developing acute respiratory distress syndrome (ARDS). |
|
References |
1. Kashyap VK, Wang Q, Setua S, Nagesh PKB, Chauhan N, Kumari S, Chowdhury P, Miller DD, Yallapu MM, Li W et al.. (2019)
Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res, 38 (1): 29. [PMID:30674344] |
2. Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, Chen H, Wu Z, Yang J, White SW, Miller DD et al.. (2018)
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities. J Med Chem, 61 (17): 7877-7891. [PMID:30122035] |